Ticagrelor S.K., co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with – acute coronary syndromes (ACS) or- a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.
Limitations of use: 90 mg twice daily during the first year after an ACS event followed by 60 mg twice daily for additional 2 years.
Disclaimer:
The images and designs presented on this website are for illustrative purposes only. Actual products may differ from those shown, including variations in color, packaging design, wording, or other visual features.The company assumes no responsibility for any such discrepancies and does not undertake to update the website to reflect changes in the actual product.
